Pages that link to "Q34488700"
Jump to navigation
Jump to search
The following pages link to Clinical Implications of the Cancer Genome (Q34488700):
Displaying 50 items.
- Somatic DNA mutation analysis in targeted therapy of solid tumours (Q26770324) (← links)
- An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts (Q26772895) (← links)
- Structural variation discovery in the cancer genome using next generation sequencing: computational solutions and perspectives (Q26991436) (← links)
- Advances in the Molecular Analysis of Soft Tissue Tumors and Clinical Implications (Q27021848) (← links)
- Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers (Q28484970) (← links)
- Public data and open source tools for multi-assay genomic investigation of disease (Q28596241) (← links)
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity (Q29547693) (← links)
- Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine (Q30513982) (← links)
- High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing (Q30514084) (← links)
- Clinical analysis and interpretation of cancer genome data (Q30617093) (← links)
- Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology (Q33837836) (← links)
- High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes (Q34050186) (← links)
- First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer (Q34104204) (← links)
- p-Medicine: From data sharing and integration via VPH models to personalized medicine (Q34140068) (← links)
- Correlation of drug-induced apoptosis assay results with oncologist treatment decisions and patient response and survival (Q34256053) (← links)
- Combinatorial drug therapy for cancer in the post-genomic era. (Q34287101) (← links)
- Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. (Q34464009) (← links)
- Mutations of epigenetic regulatory genes are common in thymic carcinomas (Q34648225) (← links)
- Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment (Q35067532) (← links)
- Personalized medicine: new genomics, old lessons (Q35082635) (← links)
- Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing (Q35178113) (← links)
- BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers (Q35453542) (← links)
- ClinSeK: a targeted variant characterization framework for clinical sequencing (Q35540606) (← links)
- Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection (Q35677556) (← links)
- An emerging toolkit for targeted cancer therapies (Q35694357) (← links)
- A Database of Gene-Environment Interactions Pertaining to Blood Lipid Traits, Cardiovascular Disease and Type 2 Diabetes. (Q35745829) (← links)
- Impact of Pre-Analytical Variables on Cancer Targeted Gene Sequencing Efficiency. (Q35852269) (← links)
- Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST (Q36015295) (← links)
- Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perils (Q36038823) (← links)
- Translating genomic information into clinical medicine: lung cancer as a paradigm (Q36354845) (← links)
- Next-Generation Testing for Cancer Risk: Perceptions, Experiences, and Needs Among Early Adopters in Community Healthcare Settings (Q36367741) (← links)
- Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. (Q36511670) (← links)
- Mechanisms of chemoresistance in cancer stem cells (Q36591484) (← links)
- Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies (Q36660664) (← links)
- New targetable oncogenes in non-small-cell lung cancer (Q36660677) (← links)
- Primary extraosseous Ewing sarcoma of the lung in children (Q36791086) (← links)
- Comparison and validation of genomic predictors for anticancer drug sensitivity (Q37039879) (← links)
- Management of incidental findings in clinical genomic sequencing (Q37148891) (← links)
- Blood-brain barrier remodeling during brain metastasis formation (Q37217055) (← links)
- Existing and emerging technologies for tumor genomic profiling (Q37255147) (← links)
- Advancing precision medicine for prostate cancer through genomics (Q37255151) (← links)
- Recent progress and clinical importance on pharmacogenetics in cancer therapy. (Q37382559) (← links)
- Genomic Disparities in Breast Cancer Among Latinas. (Q37509093) (← links)
- Target sequencing and CRISPR/Cas editing reveal simultaneous loss of UTX and UTY in urothelial bladder cancer (Q37665300) (← links)
- Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma (Q37706527) (← links)
- Somatic variation and cancer: therapies lost in the mix. (Q37885276) (← links)
- Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology (Q37886990) (← links)
- Whole cancer genome sequencing by next-generation methods (Q37932206) (← links)
- Discovery of small molecule cancer drugs: successes, challenges and opportunities (Q37996113) (← links)
- The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. (Q37996420) (← links)